📰 Celentyx Ltd News
Celentyx Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Celentyx Ltd. Real-time updates on events, politics, business and more.
April 23, 2024
According to a recent report by Market.us, the Global Drug Repurposing Market size is expected to be worth around USD 51.8 Billion by 2033 from USD 32.1 Billion in 2023, growing at a CAGR of 4.5% during the forecast period from 2024 to 2033.Drug repurposing, also known as drug repositioning or reprofiling, represent...
September 13, 2022
/PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the companys lead drug candidate ILB® to:...
September 13, 2022
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced
September 7, 2022
VIKEN, Sweden, Sept. 7, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in...
September 7, 2022
/PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the companys lead drug candidate ILB® to...
September 1, 2022
DUBLIN--(BUSINESS WIRE)--The "Global Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Drug, by Service, by Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Pancreatic), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com...
June 28, 2022
A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein attachment assay.